Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stewart, T. J.
Right arrow Articles by Leggatt, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, T. J.
Right arrow Articles by Leggatt, G. R.
[Cancer Research 63, 3058-3060, June 15, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Inhibition of Early Tumor Growth Requires J{alpha}18-positive (Natural Killer T) Cells1

Trina J. Stewart, Mark J. Smyth, Germain J. P. Fernando, Ian H. Frazer and Graham R. Leggatt2

Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, 4102 [T. J. S., G. J. P. F., I. H. F., G. R. L.], and Cancer Immunology Program, Peter MacCallum Cancer Institute, East Melbourne, Victoria, 8006 [M. J. S.], Australia


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
The role of natural killer T (NKT) cells in the immune response to tumor cells has been largely unexplored. As a model of adoptive tumor immunotherapy, cells from the draining lymph nodes of mice immunized with a tumor-specific or irrelevant antigen were transferred to naïve recipients with established tumor. Inhibition of early tumor growth (day 4) required the transfer of both CD8+ and J{alpha}18+ (NKT) cells from immunized animals without regard to immunogen. In contrast, CD8+ cells, but not J{alpha}18+ cells, were necessary for the inhibition of late tumor growth (day 8). Thus, the developing tumor changes in sensitivity to NKT-mediated events and the role for NKT cells cannot be replaced by the presence of tumor-specific cells during early tumor growth. This suggests that recruitment/activation of J{alpha}18+ NKT cells is an important consideration during the immune therapy of early stage tumors.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
NKT3 cells are a lymphocytic population that coexpress cell surface markers of both the NK- and T-cell lineage. Most murine NKT cells are either CD4+CD8- or CD4-CD8-and express a highly restricted TCR repertoire consisting of an invariant V{alpha}14J{alpha}18 TCR{alpha} chain in association with a restricted Vß repertoire (1) . The TCR on NKT cells recognizes glycolipids presented by the CD1d molecule that is expressed by many different cell types. On stimulation through the TCR, NKT cells have the capacity to produce large amounts of proinflammatory cytokines rapidly, including IFN-{gamma} and tumor necrosis factor, in addition to immunoregulatory cytokines including IL-4 and IL-10. NKT cell function and regulation is not well understood, but accumulating evidence suggests a role in the regulation and differentiation of adaptive immune responses (2) . The physiological role of NKT cells in tumor immunity may be multifaceted, with one study suggesting that NKT cell production of IL-13 suppresses the immune response to tumor cells, whereas others suggest a direct role for NKT cells in the control of methylcholanthrene-induced fibrosarcomas (3 , 4) . Our study addresses the role of adoptive immunotherapy, using mixed cell types, in the treatment of an established HPV16E7-expressing tumor, TC-1 (5) . Using this model, we have shown that different immune cells regulate tumor growth at different time points after TC-1 tumor implantation. Whereas transferred CD8+ cells are important regulators of tumor growth at all of the time points, transferred NKT cells are only necessary in the early stages of tumor development.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Mice.
Female C57BL/6, C57BL/6J-Rag1tm1Mom (Rag-1-/-), and C.B-17-Igh-1b-prkdcscid (SCID) mice were obtained at 6–8 weeks of age from the Animal Resources Centre (Perth, Western Australia, Australia). B6.J{alpha}18-/- gene targeted mice have been described previously (6) . All of the mice were housed at the Princess Alexandra Hospital Biological Research Facility (Brisbane, Queensland, Australia). All of the mice entered experiments at 6–10 weeks of age, and were age and sex matched within experiments. The animal ethics committee of the University of Queensland approved all of the experiments.

Proteins and Adjuvant.
HPV16E7GST fusion protein was prepared as described by Fernando et al. (7) . Myo (Sigma, St. Louis, MO) was prepared at 10 mg/ml in distilled water. The saponin, Quil A (Spikoside; ISCOTEC A B, Lulea, Sweden), was used as an adjuvant in all of the immunizations.

Cell Lines and Culture.
TC-1, a tumorigenic, H-2b cell line expressing the E6 and E7 proteins of HPV16 was obtained from Tzyy-Choou Wu (Ref. 5 ; John Hopkins University Medical School, Baltimore, MD). In preparation for implantation into mice, TC-1 cells were cultured to >80% confluence, harvested by trypsinization, and washed in PBS before injection. CTLs were generated from LNC and assayed as described previously (8) .

Tumor Assay.
Mice were challenged s.c. between the shoulder blades (neck scruff) with 5 x 105 TC-1 tumor cells. One hundred percent of C57BL/6 mice challenged with this tumor dose developed tumors. Tumors were allowed to establish for defined periods before i.v. transfer of LNC. Except where indicated, mice were sacrificed at day 14 after tumor implantation, and the tumor excised and weighed. Each group consisted of at least 5 mice.

Cells for adoptive transfer were generated from mice immunized s.c. in both footpads by injection of either 50 µg HPV16E7GST or Myo and 10 µg of Quil A. After 4 days, the popliteal and periaortic lymph nodes were removed, and a single cell suspension was prepared by mechanical disruption. Dissociated cells, suspended in PBS, were then transferred into the tail vein (i.v.) of tumor-bearing mice.

Lymphocyte Depletions and Antibody Staining.
CD4 and CD8 Dynabeads (Dynal Biotech Pty. Ltd., Carlton, Victoria, Australia) were used for the depletion of CD4+ and/or CD8+ cells from the LNC suspension. Depletions were performed according to manufacturer’s instructions. The remaining cells were analyzed for depletion efficiency, before transfer, by analysis of antibody stained cells on a FACSCalibur (BD Biosciences, San Jose, CA). Sample depletion efficiency was calculated as: [1 -(percentage of stained cells in the depleted group/percentage of stained cells in an untreated group)] x 100.

Statistical Analysis.
Experimental groups were compared using the two-tailed, unpaired Student’s t test. Error bars represent the SE, and Ps < 0.05 were considered significant.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Immunotherapy of TC-1 Tumor Established for 4 Days Requires CD8+ and J{alpha}18+ Cells.
TC-1 is a rapidly growing, transplantable, murine tumor expressing the E7 protein from HPV type 16. A model for adoptive immunotherapy of TC-1 tumor was established using LNC from HPV16E7 immunized mice at day 4 after immunization as effector cells. LNC from mice immunized with either HPV16E7 (tumor antigen) or Myo protein (protein control) were capable of delaying tumor growth (Fig. 1A)Citation , whereas the transfer of LNC from unimmunized mice had no apparent effect on tumor growth (Fig. 1A)Citation . In additional studies (data not shown) transfer of LNC from mice given adjuvant alone (Quil A) was sufficient to reduce growth of the TC-1 tumor. Tumor growth was also reduced more effectively by E7 immune LNC than by Myo immune LNC when measured at multiple time points after cell transfer, although neither transfer prevented eventual tumor progression (Fig. 1B)Citation . These observations suggested that immune targeting of tumor antigen improved adoptive therapy of TC-1, but was not necessary when cells were transferred at day 4 after tumor establishment.



View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1. Inhibition of tumor growth by donor LNC administered 4 days after tumor cell inoculation in the recipient is tumor antigen-nonspecific and ablated by removal of CD8+ or J{alpha}18+ cells. A, 4 days after TC-1 tumor inoculation in a recipient mouse, LNCs from donor mice immunized with either HPV16E7 (E7) or Myo (MYO), or LNCs from untreated donor mice were transferred to the recipient. The s.c. tumor mass was excised and weighed at day 14. B, donor LNC from mice immunized with either E7 ({blacktriangledown}) or Myo ({bullet}) were transferred at day 4 (indicated by the arrow) into C57BL/6 recipient mice challenged with tumor on day 0. Tumor weights were recorded at various times after tumor inoculation. Tumor-bearing recipient mice without donor cell transfer are also shown at a single time point ({blacksquare}). C and D, LNC from immunized donor mice were depleted of CD4+, CD8+, or CD4+ and CD8+ cells, or mock-depleted with control antibody (ISO) before transfer into C57BL/6 (C) or SCID (D) tumor-bearing recipient mice 4 days after tumor challenge. Fourteen days after tumor challenge, tumor masses were excised and weighed. CD8 and CD4 cell depletions were successful in removing >75% of CD8 cells and >95% of the CD4 cells as determined by flow cytometry. E, LNC from J{alpha}18-/- ({bullet}, {circ}) or J{alpha}18+/+ ({blacksquare}, {square}) mice immunized with E7 protein were stimulated with E7 peptide and IL-2 for 5 days in vitro before assaying lytic activity. Cultured LNC were assayed for lytic activity, at different E:T ratios, using E7-expressing EL4 ({blacksquare},{bullet}) or control EL4 ({square},{circ}) cell lines as targets. F, 4 days after tumor inoculation, tumor-bearing recipient mice received donor LNC from immunized J{alpha}18+/+ or J{alpha}18-/- mice. Tumors were excised and weighed at day 14. In all tumor experiments, data are representative of one of two similar experiments using 5 mice/group. Data are presented as mean; bars, ± SE. *, P < 0.05 for test group versus no transfer.

 
To ascertain whether a CD8+ cell population within transferred immune LNC contributed to delayed growth of established TC-1 tumor, LNC preparations were depleted in vitro of specific lymphocyte subsets before transfer to tumor-bearing recipients. In contrast to CD4 cell depletion (Fig. 1C)Citation , transfer of CD8+ cell-depleted immune LNC, without regard to tumor antigen specificity, did not slow tumor growth (Fig. 1C)Citation . This suggested that CD8+ cells were necessary for limiting tumor growth, although priming to tumor antigen before transfer was not necessary. Consequently, it was possible that transferred cells were assisting a recipient T-cell response directed at the E7 tumor antigen. To determine the role of recipient T and B cells in tumor immunotherapy, transfer experiments were undertaken in SCID mice lacking endogenous T and B cells. Transfer of LNC, from HPVE7 or Myo immunized mice, into tumor-bearing, SCID mice resulted in reduced tumor growth suggesting that recipient T and B cells were not necessary for limiting TC-1 tumor growth (Fig. 1D)Citation , and that transferred CD8 T cells may act directly on the tumor or via recruitment of the innate immune system.

To investigate the role of NKT cells in immune LNC-mediated control of recently established tumor, J{alpha}18-/- mice, lacking V{alpha}14 NKT cells, were immunized with E7 or Myo to generate LNC effectors. Comparable numbers of E7-specific CTLs (Fig. 1E)Citation were generated in E7 immunized J{alpha}18-/- mice and J{alpha}18+/+ mice at day 4 after immunization. In addition, the J{alpha}18+/+ mice and J{alpha}18-/- mice had similar proportions of CD4+ cells (35.9% versus 32.8%, respectively) and CD8+ cells (27.3% versus 25.7%, respectively), as well as activated CD4+CD69+ cells (8.3% versus 6.1%, respectively) and CD8+CD69+ cells (7.4% versus 7.6%, respectively) in the draining LNC after immunization. However, immune LNC from J{alpha}18-/- mice, immunized with either E7 or Myo protein, failed to alter the growth of a 4-day established TC-1 tumor, in contrast with LNC from similarly immunized J{alpha}18+/+ mice (Fig. 1F)Citation . Thus, delayed growth of a recently established tumor requires the transfer of CD8+ and J{alpha}18+ cells, and T cells induced to a tumor antigen in the absence of J{alpha}18 NKT cells fail to achieve tumor control.

One model compatible with our data would suggest that a CD8+J{alpha}18+ cell was responsible for the delay in tumor outgrowth. This was unlikely given that J{alpha}18+ NKT cells are almost exclusively CD4+, although populations of CD4-/CD8- J{alpha}18+ cells may exist (9) . Consequently, it is more likely that CD8 and J{alpha}18 proteins are expressed on separate cell types. Given the limited numbers of NKT cells in the donor LNC (based on numbers of NK1.1+ cells in the LNC transfers; data not shown), it is possible NKT cells play a role in the efficient priming of the antitumor response within the draining lymph node of the donor, before cell transfer. This role in immune priming does not apparently involve the generation of tumor antigen-specific CD8+ CTL numbers, as similar numbers of cytolytic T cells can be generated in J{alpha}18-/- mice and C57BL/6 mice (Fig. 1E)Citation . Immune priming may also include other cell types and, to this end, NKT cells have been proposed to enhance the activity of NK cells and dendritic cells (10 , 11) . Alternatively, small numbers of transferred NKT cells may sustain the immune response or enhance homing of immune cells to the tumor site in the recipient. One novel finding was that CD8+ cells specific for tumor antigen were incapable of limiting tumor growth in the absence of J{alpha}18+ cells, consistent with the idea that NKT cells coordinate the antitumor response at this early time point in tumor formation.

Consequently, we favor a model whereby NKT cells, CD8+ cells, and possibly additional cell types collaborate to prevent the outgrowth of day 4 tumor. Transferred NKT cells and/or CD8+ cells may initiate or enhance the activity of additional effector populations (i.e., NK cells or macrophages) present in either the donor or the recipient cell populations.

Immunotherapy of TC-1 Tumor Established for 8 Days Requires CD8+ Cells and Is Directed at the E7 Tumor Antigen.
To establish whether NKT and CD8+ cells also contribute to the control of more established tumors, we examined the ability of passively transferred lymphocytes to alter the growth of tumors established 8 days previously. In contrast to the immunotherapy of TC-1 tumors established for 4 days, LNC from mice immunized with Myo were unable to delay the growth of tumor when transferred at day 8 after tumor inoculation (Fig. 2, A and B)Citation . However, LNC from mice immunized with the tumor antigen (E7) were capable of inducing regression of tumor mass at this time point (Fig. 2B)Citation .



View larger version (28K):
[in this window]
[in a new window]
  		Fig. 2. Inhibition of tumor growth by donor LNC administered 8 days after tumor cell inoculation in the recipient is tumor antigen-specific and involves CD8+ cells. A, C57BL/6 mice were inoculated with TC-1 tumor cells 8 days before transfer of donor LNC from mice immunized with either E7 or MYO. Tumor was excised and weighed on day 14. B, donor LNC from mice immunized with E7 ({blacktriangledown}) or MYO ({bullet}) were transferred 8 days (indicated by the arrow) after inoculation with tumor cells into C57BL/6 recipient mice. Tumor weights were taken at various times after tumor cell challenge. Tumor-bearing recipient mice without donor cell transfer are also shown ({blacksquare}). C and D, LNC from E7-immunized mice were depleted as shown in Fig. 1CCitation before transfer into C57BL/6 (C) or RAG-1-/- (D) recipient mice 8 days after tumor challenge. E, 8 days after tumor inoculation, mice received LNC from J{alpha}18+/+ or J{alpha}18-/- mice immunized previously with E7. Tumors were excised and weighed at day 14. In all tumor experiments, data are representative of one of two similar experiments using 5 mice/group. Data represent the mean; bars, ± SE. *, P < 0.05 for test group versus no transfer.

 
Depleted LNC preparations were also transferred to animals bearing 8-day established tumors. Similar to day 4, CD8+ cell-depleted, E7-specific LNC were unable to control tumor growth suggesting a role for CD8+ cells in therapy of established day 8 tumor (Fig. 2C)Citation . Tumor growth was reduced by E7-specific LNC after treatment with a negative control antibody, and, surprisingly, by E7-specific LNC depleted of both CD4 and CD8 cells (Fig. 2C)Citation . Depletion of CD4+ cells alone from the LNC inoculum had little effect on the ability of the LNC to limit established tumor growth (day 8; Fig. 2CCitation ). Consistent with these results, CD8+ donor cells were also necessary for the control of tumor growth in RAG-1-/- mice lacking endogenous T and B cells (Fig. 2D)Citation . Furthermore, depletion of both CD4 and CD8 cells from transferred E7-specific LNC resulted in diminished tumor growth in RAG-1-/- mice as observed in C57BL/6 mice (Fig. 2, C and D)Citation .

In contrast to the observation for 4-day established tumors, transfer of LNC from E7-immunized, J{alpha}18-/- mice reduced the growth of 8-day, established tumors, suggesting that an effector mechanism independent of NKT cells was operative with established day-8 tumors (Fig. 2E)Citation .

Inhibition of growth of 8-day established tumor was exclusively mediated by tumor antigen-specific LNC, and J{alpha}18+ cells were not necessary to induce or deliver effector function. The specificity of this antitumor response contrasts with that of 4-day established tumors, and suggests that conventional TCR ligation by peptide/MHC is an important feature of this response, particularly given the requirement for CD8+ cells. An additional antitumor mechanism is revealed by depleting transferred LNC of both CD4 and CD8 cells, suggesting that this mechanism is normally suppressed by T cells. Interestingly, this alternate antitumor effect is not apparent during early tumor growth (day 4 after tumor inoculation)

In this study, we have demonstrated that the control of growth of a transplantable tumor by immune effector cells involves more than antigen-specific CD8 CTL killing of tumor cells. Activated NKT cells are therapeutically effective early in the development of the tumor, whereas tumor antigen-specific cells are required at later time points. In circumstances whereby MHC class I restricted tumor antigens are lost or down-regulated, the demonstration of additional effector mechanisms provides alternative pathways for tumor immunotherapy.


   ACKNOWLEDGMENTS
 
We thank Barbara Murray (CICR) for HPV16E7GST-protein purification, David Wiseman (CICR) and Caron Maxim (CICR) for the care of animals, and Dr. Tzyy-Choou Wu (Johns Hopkins University Medical School, Baltimore, MD) for the gift of the TC-1 cell line. We also thank Dr. Jay Berzofsky (NIH, Bethesda, MD) and Dr. Masaki Terabe (NIH, Bethesda, MD) for critical reading of the manuscript, and Prof. Masaru Taniguchi (Chiba University, Chiba, Japan) for the J{alpha}18-/- mice.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by funding from the University of Queensland. Back

2 To whom requests for reprints should be addressed, at Centre for Immunology and Cancer Research, The University of Queensland, Research Wing, Building 1, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, 4102. Phone: 61-7-3240-5393; Fax: 61-7-3240-5946; E-mail: gleggatt{at}cicr.uq.edu.au Back

3 The abbreviations used are: NKT, natural killer T; HPV, human papillomavirus; LNC, lymph node cell; Myo, myoglobin; CTL, cytotoxic T lymphocyte; CICR, Centre for Immunology and Cancer Research; NK, natural killer; TCR, T-cell receptor; IL, interleukin. Back

Received 12/20/02. Accepted 4/25/03.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Lantz O., Bendelac A. An invariant T cell receptor {alpha} chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4–8- T cells in mice and humans. J. Exp. Med., 180: 1097-1106, 1994.[Abstract/Free Full Text]
  2. Bendelac A., Rivera M. N., Park S. H., Roark J. H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol., 15: 535-562, 1997.[Medline]
  3. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D. D., Carbone D. P., Paul W. E., Berzofsky J. A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1: 515-520, 2000.[Medline]
  4. Crowe N. Y., Smyth M. J., Godfrey D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med., 196: 119-127, 2002.[Abstract/Free Full Text]
  5. Lin K. Y., Guarnieri F. G., Staveley-O’Carroll K. F., Levitsky H. I., August J. T., Pardoll D. M., Wu T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996.[Abstract/Free Full Text]
  6. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for V{alpha}14 NKT cells in IL-12-mediated rejection of tumors. Science (Wash. DC), 278: 1623-1626, 1997.[Abstract/Free Full Text]
  7. Fernando G. J., Murray B., Zhou J., Frazer I. H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol., 115: 397-403, 1999.[Medline]
  8. Leggatt G. R., Dunn L. A., De Kluyver R. L., Stewart T., Frazer I. H. Interferon-{gamma} enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol. Cell Biol., 80: 415-424, 2002.[Medline]
  9. Apostolou I., Cumano A., Gachelin G., Kourilsky P. Evidence for two subgroups of CD4-CD8- NKT cells with distinct TCR {alpha} ß repertoires and differential distribution in lymphoid tissues. J. Immunol., 165: 2481-2490, 2000.[Abstract/Free Full Text]
  10. Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano T., Taniguchi M., Nishimura T. The natural killer T (NKT) cell ligand {alpha}-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)- 12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med., 189: 1121-1128, 1999.[Abstract/Free Full Text]
  11. Smyth M. J., Crowe N. Y., Godfrey D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol., 13: 459-463, 2001.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 FASEB J.Home page
H. Wakao, R. Wakao, S. Sakata, K. Iwabuchi, A. Oda, and H. Fujita
In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer
FASEB J, July 1, 2008; 22(7): 2223 - 2231.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. J. Renukaradhya, M. A. Khan, M. Vieira, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz
Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma
Blood, June 15, 2008; 111(12): 5637 - 5645.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Berzofsky and M. Terabe
NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis
J. Immunol., March 15, 2008; 180(6): 3627 - 3635.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky
Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis
J. Immunol., October 15, 2007; 179(8): 5126 - 5136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Molling, J. A.E. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bontkes, H. J.J. van der Vliet, B. M. E. von Blomberg, R. J. Scheper, and A. J.M. van den Eertwegh
Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma
J. Clin. Oncol., March 1, 2007; 25(7): 862 - 868.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
M. Terabe, J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky
A nonclassical non-V{alpha}14J{alpha}18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
J. Exp. Med., December 19, 2005; 202(12): 1627 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
D. H. Chang, K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al.
Sustained expansion of NKT cells and antigen-specific T cells after injection of {alpha}-galactosyl-ceramide loaded mature dendritic cells in cancer patients
J. Exp. Med., May 2, 2005; 201(9): 1503 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Matsumoto, G. R. Leggatt, J. Zhong, X. Liu, R. L. de Kluyver, T. Peters, G. J. P. Fernando, A. Liem, P. F. Lambert, and I. H. Frazer
Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors
J Natl Cancer Inst, November 3, 2004; 96(21): 1611 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. E. Gumperz
CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?
J. Leukoc. Biol., August 1, 2004; 76(2): 307 - 313.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stewart, T. J.
Right arrow Articles by Leggatt, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, T. J.
Right arrow Articles by Leggatt, G. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online